Navigation Links
InterMune to Present at BMO Healthcare Conference
Date:7/30/2008

BRISBANE, Calif., July 30 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Daniel G. Welch, Chairman, CEO and President of InterMune, will present at the BMO Capital Markets 2008 Focus on Healthcare Conference in New York on August 6, 2008 at 10:00 a.m. EDT.

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at http://www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
2. InterMune to Present at Jefferies Healthcare Conference
3. InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
4. InterMune to Present at Citigroup Healthcare Conference
5. InterMune to Present at Bank of America Health Care Conference
6. InterMune to Present at Deutsche Bank Health Care Conference
7. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
8. Evotec Expands Collaboration With InterMune
9. InterMune to Present at the SIGnificant Options in Healthcare Conference
10. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
11. InterMune Announces Closing of Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals ... APTIOM TM (eslicarbazepine acetate) for use as a ... in patients with epilepsy who are not satisfactorily controlled ... for use in patients under 18 years of age. ... common neurological disorders and according to Epilepsy Canada, it ...
(Date:7/10/2014)... UK (PRWEB) July 10, 2014 ... 21st Century Medicine Forum on ‘Commercialising Longevity Research’ ... and entrepreneurs to the London Bioscience Innovation Center ... Research Foundation and Aging Analytics Ltd. The meeting ... investment in translational research for age-related disease, as ...
(Date:7/10/2014)... Los Angeles, CA (PRWEB) July 10, 2014 ... Analytical and Bioanalytical techniques during 18-20 August, 2014 at ... to critically review the recent developments in Analytical & ... across the globe. , Speaking on this occasion, Dr. ... that Analytica Acta conference is a remarkable one ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a ... brands, today announced that it has acquired the Slim-Fast ... in the business. Terms of the transaction were not ... and meal replacement business that markets ready-to-drink shakes, powders, ... North America and in the ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2
... DUBLIN, August 3, 2010 , - Proposed recommended cash acquisition ... a fully diluted equity purchase price of, EUR428 ... date, Movetis held EUR100 million in cash; based on this ... be EUR328 million, - Strong strategic fit with Shire,s growing ...
... ,, ROCKVILLE, Md. , Aug. 2 Vanda Pharmaceuticals Inc. ... the development and commercialization of products for central nervous system disorders, today announced ... August 5, 2010 , before the market opens. A full text copy of ... , , ...
... , CHICAGO and HOBOKEN, N.J. , Aug. 2 ... of the Octapharma 25th Anniversary Grants Program is the Rush ... Octapharma grants program supports clinical or pre-clinical research focused on human protein therapies ... , , ...
Cached Biology Technology:Shire Proposes to Expand Specialist Gastrointestinal Portfolio 2Shire Proposes to Expand Specialist Gastrointestinal Portfolio 3Shire Proposes to Expand Specialist Gastrointestinal Portfolio 4Shire Proposes to Expand Specialist Gastrointestinal Portfolio 5Shire Proposes to Expand Specialist Gastrointestinal Portfolio 6Shire Proposes to Expand Specialist Gastrointestinal Portfolio 7Shire Proposes to Expand Specialist Gastrointestinal Portfolio 8Shire Proposes to Expand Specialist Gastrointestinal Portfolio 9Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010 2Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 2Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 3Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 4Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 5Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 6
(Date:7/11/2014)... Canyon fire started near the City of Entiat on ... resources, the fire quickly grew to over 1,000 acres ... the fire is under investigation by the Washington Department ... with existing local resources in developing fire control strategies ... (USFS), Washington State Department of Natural Resources, (WA DNR), ...
(Date:7/11/2014)... of Chicago is creating a new professorship in ... University,s Institute for Molecular Engineering and the Marine ... from the Millicent and Eugene Bell Foundation., The ... within the Institute for Molecular Engineering. That endowed ... at the MBL,s Eugene Bell Center for Regenerative ...
(Date:7/11/2014)... have set a "mouse TRAP" to capture the early ... study published in the Journal of Clinical Investigation ... called TRAP to extract cellular and genetic information from ... at the Rockefeller Institute for Medical Research in 2008, ... machinery, or ribosomes, of the cell type of interest. ...
Breaking Biology News(10 mins):New professorship in tissue engineering links molecular engineering, marine biology 2
... HONOLULU While the iconic Haleakalā silversword plant made a ... a period of substantial climate-related decline. New research published this ... the silversword in its native habitat. Known for its ... single reproductive event at the end of its life, at ...
... structural similarity to asbestos, have been alleviated following research ... In a new study, published today in ... that the asbestos-like reactivity and pathogenicity reported for long, ... is modified and their effective length is reduced as ...
... DENVER Recent studies have demonstrated that molecular-targeted agents, ... inhibitors (TKI), may prolong survival of selected patients based ... EGFR gene is known as a predictive marker for ... EGFR mutations are prognostic factors for non-small cell lung ...
Cached Biology News:Global warming may have severe consequences for rare Haleakalā silverswords 2Chemistry resolves toxic concerns about carbon nanotubes 2EGFR mutation not prognostic factor in non-small cell lung cancer 2
The PxE Thermal Cycler (PxE) is a licensed 96 well PCR machine, developed to provide all fundamental features for value for money thermal cycling....
... Thermo Electron's most advanced personal gradient option ... use sophisticated onboard software and a large ... offer performance, accuracy and simplicity in thermal ... customer driven features built up on years ...
For testing the AQUA technique on your MS instruments....
The Lambda Control Kit contains lambda DNA and two 25mer primers, which can be used to amplify a 500bp fragment. The lambda DNA is purified by CsCl gradient centrifugation and organic extraction foll...
Biology Products: